Intensive and Critical Care Nursing
Volume 22, Issue 1 , Pages 59-62, February 2006

Caspofungin in the treatment of invasive fungal infections

  • Simon Keady

      Affiliations

    • Women and Children's Services, University College London Hospitals NHS Foundation Trust, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • Meera Thacker

      Affiliations

    • Critical Care Services, Royal Free Hampstead NHS Trust, UK

Received 4 May 2005; accepted 10 May 2005.

Summary 

Caspofungin is a member of a new class of antifungals called Echinocandins and is the first to have marketing authorisation in the United Kingdom.

This article reviews the clinical efficacy, side effect profile, dosing and administration schedule of caspofungin. The article also discusses the warnings and precautions associated with the use of this drug.

Caspofungin is an effective treatment option in the management of fungal infections.

Keywords: Caspofungin, Fungal, Infection, Treatment, Intensive care, Adults, Children

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0964-3397(05)00062-5

doi:10.1016/j.iccn.2005.05.003

Intensive and Critical Care Nursing
Volume 22, Issue 1 , Pages 59-62, February 2006

Article Tools